Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
A major phase 3 trial finds nivolumab + chemo falls short in bladder cancer. The ENERGIZE trial showed that adding nivolumab (Opdivo) to standard gemcitabine-cisplatin chemotherapy did not significantly improve pathologic complete response rates or event-free survival in muscle-invasive bladder cancer. However, circulating tumor DNA emerged as a promising prognostic biomarker.
The long-awaited ENERGIZE phase 3 trial has delivered a disappointing result: adding the immunotherapy nivolumab (Opdivo) to standard gemcitabine-cisplatin (GC) chemotherapy — before and after surgery — did not significantly improve outcomes in patients with previously untreated muscle-invasive bladder cancer (MIBC). Both co-primary endpoints, pathologic complete response (pCR) rate and event-free survival (EFS), missed their prespecified thresholds for statistical significance, and overall survival showed no meaningful difference between arms.
While pCR rates were numerically higher with nivolumab (39.1% vs. 29.6%), the difference didn't hold up after statistical adjustment. EFS and OS curves were nearly identical at 36 months, and the safety profile was notably worse in the nivolumab arm, with higher rates of serious adverse events.
By the Numbers:
Why it matters: ENERGIZE reinforces that simply layering checkpoint inhibitors onto cisplatin-based chemo may not be the winning formula for MIBC. With pembrolizumab plus enfortumab vedotin already approved in this space, the field is shifting — and ctDNA's emergence as a prognostic tool could help guide smarter treatment decisions going forward.
